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Purpose 
The purpose of this technical report is to provide an analysis of the available information on 
methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate — also 
known as methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido]butanoate 
— (MDMB-4en-PINACA), a synthetic cannabinoid receptor agonist (synthetic cannabinoid) 
that has recently emerged on the drug market in Europe, in order to support the risk 
assessment of the substance which has been requested by the European Commission in 
accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). 
Parts of this report were prepared under an EMCDDA contract (ref. CT.20.SAS.0108.1.0). 
Statement regarding the United Kingdom 
The reference period for this technical report includes 2020 (up to 24 November 2020). The 
United Kingdom left the European Union as of 1 February 2020. However, during the 
transitional period, the United Kingdom continues to participate in the European Union Early 
Warning System on new psychoactive substances. Unless stated otherwise, for the purpose 
of this report, the term ‘Member States ’shall include the United Kingdom. 
Information sources 
The information in this technical report is derived from: 
• Information reported by the Member States, Turkey, and Norway to the EMCDDA and 
Europol in accordance with the requirements of Article 5a and Article 5b of Regulation 
(EC) No 1920/2006 (as amended) 
• Information reported by the European Medicines Agency (EMA), the European Chemicals 
Agency (ECHA), the European Centre for Disease Prevention and Control (ECDC), and 
the European Food Safety Authority (EFSA) to the EMCDDA in accordance with the 
requirements of Article 5b of Regulation (EC) No 1920/2006 (as amended) 
• Information collected by the EMCDDA through searches of open source information, 
including the scientific and medical literature, patents, official reports, grey literature, online 
drug discussion forums and related websites, and online vendors selling MDMB-4en-
PINACA. 
Search strategy 
Literature searches used both chemical structure and textual queries in online databases; 
searches were conducted in October 2020. The retrieved publications were then scanned for 
additional relevant references (snowballing technique). 
SciFinder® and Reaxys were searched by exact structure-based search. PubMed, Web of 
Science and Google Scholar were searched for ‘MDMB-4en-PINACA’, IUPAC names, and 
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the various other code names stated in this document. The references were screened for 
relevance and included in the review where appropriate.  
Additionally, the scientific networks of the authors were contacted to obtain information. 
Terminology and definitions 
The terminology and definitions used in this technical report are based on those used for the 
operation of the EU Early Warning System on new psychoactive substances, including those 
related to relevant internal EMCDDA processes. They can be accessed at: 
http://www.emcdda.europa.eu/system/files/publications/12213/downloads/Guidance%20Not
e%201-%20Terminology%20and%20definitions.pdf (EMCDDA, 2019). 
Unless otherwise indicated, the terms and definitions are for operational use only and do not 
have legal meaning. They may differ from those used in other settings and by other 
organisations (EMCDDA, 2019). 
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1. Summary 
Synthetic cannabinoid receptor agonists (synthetic cannabinoids), such as MDMB-4en-
PINACA, are a group of substances that mimic the effects of tetrahydrocannabinol (THC), 
which is a substance found in cannabis (1). THC is responsible for many of the psychoactive 
effects of cannabis which are dose-dependent and include relaxation, euphoria, distorted 
perception of time and impaired motor performance (the feeling of being 'stoned' or 'high'), 
as well as confusion, anxiety, occasional hallucinations and paranoia, dry mouth, bloodshot 
eyes, and cardiovascular effects (Gaoni and Mechoulam, 1964; Huestis et al., 2001; 
Pertwee, 2014). THC causes these effects by activating a receptor in the brain called the 
cannabinoid receptor type 1 (CB1 receptor) (Huestis et al., 2001; Pertwee, 2005a). This 
receptor is part of a signalling system in the body called the endocannabinoid system, which 
helps regulate, among other things, behaviour, mood, pain, appetite, sleep, and the immune 
system (Pertwee, 2015) (2). Because synthetic cannabinoids activate the CB1 receptor in a 
similar way to THC, some of their effects appear to be similar to cannabis. Most prominently, 
they are able to create a feeling of being ‘stoned’.  
Synthetic cannabinoids were originally developed to study the endocannabinoid system, as 
well as provide insights into disease states, and to help develop new medicines (Pertwee, 
2005a; Pertwee, 2005b; Pertwee, 2015; Reggio, 2009). In around 2006, some of these 
substances began to appear in Europe in products called ‘Spice’ that were sold as ‘legal’ 
replacements to cannabis (Auwärter et al., 2009; EMCDDA, 2009; Jack, 2009). In these 
products, synthetic cannabinoids were found to be mixed with plant (herbal) material which 
could then be smoked as cigarettes (‘joints’) (Auwärter et al., 2009; EMCDDA, 2009; 
EMCDDA, 2017; Jack, 2009). Such products have been referred to by a variety of names 
that depend on the country, region, product type, brand names, and user groups. Names 
include: ‘smoking mixtures’, ‘smoking mixtures’, ‘herbal incense’, ‘synthetic cannabis’, ‘legal 
weed’, and ‘K2’. A common name used in Hungary is ‘magic tobacco’; in France ‘chimique’; 
in Turkey, ‘Bonsai’; whereas in Birmingham, United Kingdom, the name ‘Black Mamba ’or 
simply ‘Mamba’ is used. Since 2008, more than 200 synthetic cannabinoids have been 
identified on the drug market in hundreds of different products. They are the largest group of 
substances that are monitored by the EMCDDA through the European Union Early Warning 
System on New Psychoactive Substances (EU Early Warning System). In recent years, 
alongside smoking mixtures, new dosage forms, including e-liquids for vaping using 
electronic cigarettes, as well as paper (including blotters) impregnated with synthetic 
 
(1) (–)-trans-Δ9-tetrahydrocannabinol.  
(2) The endocannabinoid system helps regulate a large number functions in the body. It consists of the cannabinoid CB1 and 
CB2 receptors, the endocannabinoids (such as anandamide) which act as endogenous agonists for these receptors, and the 
processes responsible for endocannabinoid biosynthesis, cellular uptake, and metabolism. Important exogenous agonists for 
the cannabinoid receptors are (–)-trans-Δ9-tetrahydrocannabinol (THC) which is the major active substance in cannabis, and 
the synthetic cannabinoids found in herbal mixtures smoked like cannabis. Data from laboratory studies suggests that the 
endocannabinoid system is involved in important biological processes many of which await exploration. For example, in 
response to some diseases, the body increases the amount of endocannabinoids it produces which can reduce unwanted 
symptoms or slow disease progression (Pertwee, 2005a; Pertwee, 2005b; Pertwee, 2015). It has also been recognized that 
endocannabinoids, as well as the structurally distinct phytocannabinoids and synthetic cannabinoids, which show an 
astonishing structural diversity, affect other neurotransmitter systems, such as the dopaminergic, glutamatergic, and 
GABAergic systems.  
6 
 
cannabinoids, have appeared on the drug market.  
In Europe, MDMB-4en-PINACA is monitored as a new psychoactive substance by the 
EMCDDA in accordance with Council Framework Decision 2004/757/JHA (as amended) and 
Regulation (EC) No 1920/2006 (as amended) (EMCDDA, 2020b). The substance has been 
available on the drug market in Europe since at least 2017. There is limited information on 
the substance, in particular formal epidemiological studies have not been conducted which 
limits understanding of the use and patterns of use of MDMB-4en-PINACA. 
It is important to note that the presence of MDMB-4en-PINACA on the market and the extent 
of its involvement in serious adverse events (such as from acute poisonings presenting to 
hospital emergency rooms and medico-legal death investigations) may be undetected since 
the substance is not routinely screened for in some laboratories. It is also important to note 
that, in some settings, the ongoing COVID-19 pandemic caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) (ECDC, 2020; EMCDDA, 2020d; WHO, 
2020b) may have reduced the capacity of early warning systems, including forensic science 
and toxicology laboratories, to detect and report events involving MDMB-4en-PINACA. 
As of November 2020, MDMB-4en-PINACA has been identified in twenty-one Member 
States as well as Norway and Turkey; 770 seizures have been reported, which include 
approximately 47 kg of powder and 4.7 kg of smoking mixtures. Although MDMB-4en-
PINACA was first identified on the drug market in 2017, it was only in 2019 that a large 
number of first identifications in Member States were reported. In addition, it was during 
2020 that there was a large increase in the quantity of MDMB-4en-PINACA seized by 
customs, with approximately 99% of the total amount of powder seized by customs (44 kg) 
having occurred during the year. 
Although MDMB-4en-PINACA has not been formally studied in humans, limited information 
suggests that MDMB-4en-PINACA is a potent CB1 receptor agonist and, as such, shares 
some pharmacological similarities with THC and other synthetic cannabinoids. Compared to 
cannabis, severe and fatal poisoning appears to be more common with synthetic 
cannabinoids. Poisoning may include rapid loss of consciousness/coma, cardiovascular 
effects (such as hypertension, tachycardia, bradycardia, chest pain, myocardial infarction, 
and stroke), seizures and convulsions, vomiting (including hyperemesis), delirium, agitation, 
psychosis, and, aggressive and violent behaviour. Sudden death has also been reported. 
There is no known antidote to poisoning caused by synthetic cannabinoids and thus the 
treatment of an overdose is the same as that of cannabis toxicity: supportive treatment and 
serial reassessment of the airway and neurological signs. Because of their high potency and 
the unintentionally high doses that users may be exposed to, synthetic cannabinoids can 
pose a high risk of severe poisoning, which in some cases can be life-threatening or even 
fatal. These factors can also be responsible for the outbreaks of mass poisonings seen with 
synthetic cannabinoids. Such outbreaks have the potential to overwhelm local healthcare 
systems, which is of particular concern given the ongoing COVID-19 pandemic and the 
additional burden already on healthcare systems.  
There is no information on the chronic health effects of MDMB-4en-PINACA. The chronic 
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health risks might share some similarities to those seen with cannabis and other synthetic 
cannabinoids; this may include dependence. 
A total of eleven acute non-fatal poisonings with confirmed exposure to MDMB-4en-PINACA 
have been reported to the EMCDDA by one Member State, the United Kingdom. All the 
cases included clinical features of poisoning similar to those reported for synthetic 
cannabinoids. In all cases other substances were identified, including other synthetic 
cannabinoids. In ten of the cases, the poisoning was considered life-threatening and 
required hospitalisation of the patient. 
A total of twelve deaths with confirmed exposure to MDMB-4en-PINACA have been reported 
to the EMCDDA by three Member States: Hungary, Sweden, and the United Kingdom. The 
deaths occurred between January 2019 and August 2020. In some of the cases, MDMB-
4en-PINACA was reported to be the cause of death or contributed to the death. 
The available information suggests that MDMB-4en-PINACA is manufactured by chemical 
companies based in China. It is imported into Europe as bulk powders and then sold and 
distributed in wholesale and retail amounts within Europe either as a powder for processing 
into products or finished consumers products. There are three main types of products 
containing MDMB-4en-PINACA that are available on the drug market:  
• smoking mixtures, where MDMB-4en-PINACA is mixed with herbal plant material or 
tobacco that is then smoked or inhaled from a vaporiser (similar to herbal cannabis, the 
mixture is usually prepared for smoking as a hand-rolled cigarette (‘joint’));  
• e-liquids, where a solution of MDMB-4en-PINACA is prepared by mixing it with a solvent, 
which is then inhaled using an e-cigarette; and  
• paper impregnated with MDMB-4en-PINACA which can then be smoked or vaped. This is 
a commonly used approach to smuggle synthetic cannabinoids into prison in some 
countries. 
To a lesser extent, users may prepare their own similar products using MDMB-4en-PINACA 
purchased from a vendor or dealer. 
The available information suggests that MDMB-4en-PINACA may be used by cannabis 
users, by those who are regularly subjected to drug testing procedures (including those in 
prison), and by people who self-experiment with a range of psychoactive substances (so-
called ‘psychonauts’). The substance may also be used by high risk drug users and other 
marginalised groups, such as people experiencing homelessness and prisoners, as 
synthetic cannabinoids are typically readily available, and have gained a reputation for 
causing profound intoxication while being comparatively cheaper to other drugs. Although 
limited, there is some information to suggest a recent increase in vaping of synthetic 
cannabinoids using electronic cigarettes by young people, including teenagers, in some 
Member States; in some cases, the users believed that they were using cannabidiol (CBD) 
or THC. 
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There is no information whether or not criminal groups are involved in the manufacture, 
trafficking, and distribution of MDMB-4en-PINACA within Europe (EMCDDA, 2020b).  
The effect of the ongoing COVID-19 pandemic (ECDC, 2020; EMCDDA, 2020d; WHO, 
2020b) on the manufacture, trafficking, distribution, and use of MDMB-4en-PINACA is 
currently unknown. However, seizures of bulk powders by European national customs 
agencies during the pandemic suggests that it continues to be imported into and distributed 
within Europe. It is possible, that in case of a reduced availability of cannabis and other 
synthetic cannabinoids in Europe, criminal groups, as well as drug users, may use a range 
of replacement substances, including MDMB-4en-PINACA. 
There is no information on the social harms that may be caused by MDMB-4en-PINACA. 
Despite this, it is likely that some of the risks are similar to those associated with the use of 
cannabis and other synthetic cannabinoids. For example, in prisons, alongside the adverse 
health effects, such as acute poisonings, the market in synthetic cannabinoids has been 
linked to an increase in bullying and debt, as well as aggression and violence. In some 
cases this has caused a serious threat to the overall safety and security of the prison 
environment. As such, it is a concern given that six Member States reported seizures of 
MDMB-4en-PINACA in prisons and other custodial settings, and, that overall, approximately 
15 % of all the seizures of MDMB-4en-PINACA made by police occurred in these settings. 
Based on the available information, it appears that MDMB-4en-PINACA is not an active 
substance in a medicinal product for human use or in a veterinary medicinal product in 
Europe. However, although unlikely, the use of MDMB-4en-PINACA as an active substance 
in medicinal products prepared extemporaneously or in investigational medicinal products 
cannot be excluded in some Member States (EMCDDA, 2020b). There is currently no 
information that suggests MDMB-4en-PINACA is used for legitimate purposes other than 
research or forensic application (EMCDDA, 2020b). 
MDMB-4en-PINACA is not controlled under the United Nations Single Convention on 
Narcotic Drugs, 1961, as amended by the 1972 Protocol, nor the Convention on 
Psychotropic Substances of 1971 (‘United Nations system’) (UNODC, 2020a; UNODC, 
2020b). MDMB-4en-PINACA was assessed at the 43rd meeting of the WHO Expert 
Committee on Drug Dependence (ECDD) that was held in October 2020 (WHO, 2020a).  
MDMB-4en-PINACA is subject to restrictive measures in fifteen Member States:  
• in Croatia, Cyprus, Finland, France, Italy, Latvia, Luxembourg, Poland, Sweden, and the 
United Kingdom the substance is controlled under drug control legislation;  
• in Lithuania it is controlled under medicines legislation;  
• in the Austria, Belgium, Germany, and Hungary it is controlled by new psychoactive 
substance legislation.  
In addition, MDMB-4en-PINACA is controlled under medicines legislation in Norway and 
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under drug control legislation in Turkey. It is unknown if MDMB-4en-PINACA is controlled in 
China, where at least some of the substance on the European market appears to have been 
sourced from (EMCDDA, 2020b). 
2. Chemical and physical properties, methods and the precursors used 
for manufacture or extraction  
2.1 Background 
Methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-
4en-PINACA) (3) – also known as methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-
carboxamido]butanoate (Figure 1) – is a synthetic cannabinoid which does not appear to 
have a history in the scientific literature. It is structurally related to compounds of the 
indazole-3-carboxamide class that feature pendant amino acid esters (methyl L-tert-
leucinate) developed by Pfizer Inc. and published in a 2009 patent (e.g. compounds 125-
130; Buchler et al., 2009). The substances described in the patent literature make reference 
to compounds that only show the (S)-configuration (Buchler et al., 2009). As far as it is 
known, synthetic cannabinoids available on the drug market have generally been found to 
retain the (S)-configuration although the presence of (R)-enantiomers or racemic mixtures 
cannot be excluded. According to information received by EMCDDA, MDMB-4en-PINACA 
has been available on the European drug market at least since 2017 although there has 
been a significant increase in the number of Member States identifying the substance for the 
first time since 2019 (EMCDDA, 2020b; EMCDDA, 2020c).  
MDMB-4en-PINACA is structurally related to 5F-MDMB-PINACA (5F-ADB) (Figure 1) (4). 
5F-MDMB-PINACA was formally notified in January 2015 and underwent EMCDDA risk 
assessment in November 2017 following reports of increasing availability and serious harms 
in Europe, including 28 deaths (EMCDDA, 2018). In March 2018, it was placed in Schedule 
II of the 1971 United Nations Single Convention on Psychotropic Substances (INCB, 2019) 
after undergoing a critical review by the World Health Organization’s (WHO) Expert 
Committee on Drug Dependence (ECDD) in November 2017 (WHO, 2017). In October 
2020, MDMB-4en-PINACA underwent a Critical Review by WHO’s ECDD (WHO, 2020a). 
MDMB-4en-PINACA is also structurally related to 4F-MDMB-BICA (5), MDMB-PINACA) (6), 
4F-MDMB-BINACA (7), and 5F-MDMB-PICA (5F-MDMB-2201) (8). The latter two substances 
were placed in Schedule II of the 1971 United Nations Single Convention on Psychotropic 
Substances (CND, 2020) after undergoing a critical review by the WHO’s ECDD in October 
 
(3) MDMB-4en-PINACA and many other synthetic cannabinoid receptor agonists described in this report contain one 
asymmetric carbon atom which gives rise to (S)- and (R)-enantiomers. The code names described in this report do not include 
the designated, absolute configuration since the available data were not consistently available to EMCDDA.  
(4) 5F-MDMB-PINACA IUPAC name: methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate 
(5) 4F-MDMB-BICA IUPAC name: methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate  
(6) MDMB-PINACA IUPAC name: methyl 3,3-dimethyl-2-[(1-pentyl-1H-indazole-3-carbonyl)amino]butanoate 
(7) 4F-MDMB-BINACA IUPAC name: methyl 2-{[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate 
(8) 5F-MDMB-PICA IUPAC name: methyl 2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate  
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2019 (WHO, 2019a; WHO, 2019b). In 2020, the EMCDDA also launched an initial report on 
4F-MDMB-BICA (5) in accordance with Article 5b of Regulation (EC) No 1920/2006 (as 
amended) (EMCDDA, 2020a).  
2.2 Names and chemical structure 
MDMB-4en-PINACA is a synthetic cannabinoid. The MDMB-4en-PINACA code name for the 
substance is derived from its structural features: a methyl 3,3-dimethylbutanoate linked 
group (MDMB), a terminal alkene (4en), a modified N-pentyl tail (P), an indazole core (INA), 
and a carboxamide linker (CA).  
Figure 1. Chemical structure and molecular information of MDMB-4en-PINACA and 5F-
MDMB-PINACA (5F-ADB)  
MDMB-4en-PINACA 
 
 
5F-MDMB-PINACA (5F-ADB) 
 
 
Molecular formula: C20H27N3O3 Molecular formula: C20H28FN3O3 
Molecular weight: 357.45  Molecular weight: 377.45 
Monoisotopic mass: 357.2052 Monoisotopic mass: 377.2115 
 
Common name:  
MDMB-4en-PINACA 
Systematic (IUPAC) name:  
Methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate 
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Other chemical names:  
Methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido]butanoate  
Methyl 3-methyl-N-[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]valinate 
Methyl 3-methyl-N-[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]-L-valinate ((S)-
enantiomer);  
Methyl 3-methyl-N-[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]-D-valinate ((R)-
enantiomer);  
Methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazol-3-yl]formamido}butanoate  
Methyl N-{[1-(pent-4-en-1-yl)-1H-indazole-3-yl]carbonyl}-3-methylvalinate;  
Methyl 2-[1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate;  
N-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-
carboxamide;  
Other names:  
MDMB-4en-PINACA 
(4-en) ABD-PINACA 
ADB-PINACA-A  
(Pentyl-4-en) MDMB-PINACA  
MDMB-PENINACA 
MDMB-PINACA N1-pentyl-4-en isomer 
5-CL-ADB-A [sic](9) 
At least historically, a common slang name for smoking mixtures containing synthetic 
cannabinoids in some countries is ‘Spice’ — which is a reference to the most common brand 
name used for these types of products when they first appeared on the market. Many other 
names are now used and depend on the country, region, product type, brand names, and 
user groups. These include: ‘smoking mixtures’,‘ herbal smoking mixtures’, ‘herbal incense’, 
‘synthetic cannabis’,‘ legal weed’, and‘ K2’. A common name used in Hungary is ‘magic 
 
(9) Potentially confusing code name though it appears to be advertised as MDMB-4en-PINACA by some Internet retailers. The 
IUPAC name for 5Cl-ADB (5Cl-MDMB-PINACA) is methyl 2-{[1-(5-chloropentyl)-1H-indazole-3-carbonyl]amino}-3,3-
dimethylbutanoate. It is the chloro analogue of 5F-MDMB-PINACA (5F-ADB) (Figure 1). The exact meaning or purpose of the ‘-
A‘ suffix in ‘5-CL-ADB-A‘ is unclear though one suggestion advertised by some retailers included ‘amylene‘ (2-methylbut-2-
ene). It does not exactly capture the structural nature of the tail group but ‘5-CL-ADB-A‘ appears to be used synonymously for 
MDMB-4en-PINACA in some cases.  
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tobacco’; in France ‘chimique’; in Turkey, ‘Bonsai’; whereas in Birmingham, United Kingdom, 
the name ‘Black Mamba ’or simply ‘Mamba ’is used. 
In France, liquids containing synthetic cannabinoids may be sold under the street name 
‘PTC ’(from the French, ‘pète ton crâne’). At least one such sample containing MDMB-4en-
PINACA was reported. Two additional collected samples of unknown physical form (also 
containing 5F-MDMB-PICA (8)) were sold as ‘Chimique’. 
In Germany, ‘legal high ’products brands containing MDMB-4en-PINACA included ‘Pico 
Bello Extra Strong ’(seized in 2017, containing 5F-ADB and 5F-ADB-PINACA), ‘Pico Bello 
Made In Holland ’(3 seizures, containing also 5F-MDMB-PICA (8)). One sample was 
purchased as ‘5CL-ADB-A ’(9)). One seized sample determined to be MDMB-4en-PINACA 
was labelled incorrectly as ‘5F-MDMB-2201 ’(5F-MDMB-PICA). 
In the United States, MDMB-4en-PINACA has been detected in a product labelled as ‘Heavy 
Weight (WHO 2020a).  
Product names cannot be considered a reliable source of information regarding the actual 
substances present in such products since the compositions of such products might be 
subject to significant variations in contents (e.g. Moosmann et al., 2015; Frinculescu et al., 
2017). 
Chemical Abstracts Service (CAS) registry numbers:  
2504100-70-1 ((S)-enantiomer) 
2504100-73-4 ((R)-enantiomer) 
IUPAC International Chemical Identifier Key (InCHI Key): 
LWOCBHBFWNGPGM-UHFFFAOYSA-N 
Simplified Molecular-Input Line-Entry System (SMILES):  
CC(C(C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C12)CCCC=C)(C)C (10)  
2.3 Physical properties 
In its pure form MDMB-4en-PINACA has been described as a neat solid (Cayman Chemical 
Company, 2020b), a powder (NFL Ljubljana, 2018), and a white powder (Watanabe et al., 
2019). It has also been described as a tan and yellow/brown powder (WHO, 2020a). Seized 
and collected samples determined to contain MDMB-4en-PINACA have been described as 
white, beige, yellow and orange powders (EMCDDA, 2020a; EMCDDA, 2020b). 
 
(10) Generated from IUPAC name by OPSIN: Open Parser for Systematic IUPAC nomenclature (http://opsin.ch.cam.ac.uk) 
(Lowe et al., 2011). 
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Information available on the lipophilicity, melting and boiling points or other physico-chemical 
properties of MDMB-4en-PINACA, with the exception of its solubility, could not be identified. 
It has been reported to be soluble in dichloromethane, methanol, and partially in water 
(Krotulski et al., 2019; NFL Ljubljana, 2018; Norman et al., 2020b) but also deuterated 
chloroform (Antonides et al., 2020; Norman et al., 2020a; Norman et al., 2020b). (S)-MDMB-
4en-PINACA has also been described as a colourless oil (Stove and Banister, personal 
communication) (11).  
Information involving the analysis of seized and collected samples received by EMCDDA 
suggests that MDMB-4en-PINACA has been detected in e-liquids for use electronic 
cigarettes, powders, smoking mixtures, and impregnated papers and cards (including 
blotters) (EMCDDA, 2020b).  
2.4 Methods and chemical precursors used for the manufacture or extraction 
No information was reported by the Member States, Norway, or Turkey about the chemical 
precursors or manufacturing methods used to make the MDMB-4en-PINACA which has 
been identified within Europe. However, the synthesis of both (S)- and (R)-MDMB-4en-
PINACA enantiomers has been recently described (Antonides et al., 2020) (Stove and 
Banister, personal communication (10)), following previously established procedures (e.g. 
Banister et al., 2016; Buchler et al., 2009) (Figure 2).  
Methyl 1H-indazole-3-carboxylate (available commercially or might be prepared from various 
precursors) (1) undergoes N-alkylation with 5-bromopent-1-ene and followed by hydrolysis 
to the carboxylic acid intermediate (3). Coupling with methyl L-tert-leucinate (methyl (2S)-2-
amino-3,3-dimethylbutanoate) (12) gives (S)-MDMB-4en-PINACA (4) (Figure 2). Coupling 
with methyl D-tert-leucinate yields (R)-MDMB-4en-PINACA. 
 
Figure 2. Synthesis route for MDMB-4en-PINACA ((S)-enantiomer) starting from methyl 1H-indazole-3-
carboxylate (Antonides et al., 2020) and Stove and Banister (personal communication (11)). Reagents: (a) tert-
butoxide or NaH, THF or DMF, 5-bromopent-1-ene; (b) 1 M aq. NaOH, MeOH, reflux or room temperature; (c) 
methyl L-tert-leucinate, EDC·HCl, HOBt, DIPEA, DMSO or EDC·HCl, HOBt·H2O, Et3N, DMF at room 
temperature. For the preparation of the (R)-enantiomer (Antonides et al. 2020), the coupling reaction involves the 
 
(11) Cannaert et al., 2020  
(12) (S)-L-tert-Leucine is widely used for the manufacture of antiviral medicines and is produced mainly in China in large 
quantities. This may explain the choice of this precursor for the synthesis of MDMB-4en-PINACA and other related synthetic 
cannabinoids that have been reported to the EU Early Warning System. 
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use of methyl D-tert-leucinate instead.  
2.5 Methods for identification and analysis 
Analytical data for MDMB-4en-PINACA and methods for its identification have been 
published in the scientific literature and are in the public domain (Table 1). The analysis of 
biological samples requires the use of sensitive analytical methods, e.g. liquid 
chromatography coupled to (tandem) mass spectrometry approaches (high and low 
resolution). (S)-MDMB-4en-PINACA is available as reference material from commercial 
suppliers. The EMCDDA has not received information about the enantiomeric composition of 
MDMB-4en-PINACA-containing products, although the presence of the (S)-enantiomer, 
similar to most other closely related synthetic cannabinoid receptor agonists available on the 
market, seems likely. However, the presence of the (R)-enantiomer or the racemic mixture 
cannot not be excluded in the absence of further information. Chiral profiling analyses 
carried out on paper samples seized in three Scottish prisons confirmed the presence of the 
(S)-enantiomer (McKenzie, 2020).  
In some biological specimens, the parent molecule might not always be detectable due to 
ester hydrolysis which gives rise to the formation of an acidic transformation product (13), a 
phenomenon described for other synthetic cannabinoids with such ester moieties (e.g. Ong 
et al. 2020). However, the detection of this metabolite/degradation product alone might not 
be sufficient for unambiguous identification as it might also arise from various other ester 
and amide analogues (see, for example, Diao and Huestis, 2019).  
Table 1. Detections and analytical data associated with the detection and chemical analysis of 
MDMB-4en-PINACA (amongst other substances) available in the scientific literature and 
public domain 
Techniques a Comment  Reference 
GC-MS; IR; NMR  Analysis of test purchased material NFL Ljubljana 
(2018) 
EI-MS; LC-MS Analysis of reference material and blood 
samples 
Krotulski et al. 
(2019) 
LC-MS In vitro metabolism study and analysis of a case 
sample 
Watanabe et al. 
(2019) 
GC-MS; NMR; LC-UV-
MS 
Analysis of synthesised (S)- and (R)-MDMB-
4en-PINACA 
Antonides et al. 
(2020) 
GC-MS Analysis of reference material Cayman Chemical 
Company (2020a) 
 
(13) Ester hydrolysis product IUPAC name: 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoic acid 
15 
 
LC-MS Analysis of case samples Krotulski et al. 
(2020a) 
GC-MS; NMR; LC-UV-
MS 
Analysis of seized samples (impregnated 
papers) and analysis of synthesised (S)- and 
(R)-MDMB-4en-PINACA 
Norman et al. 
(2020b) 
IMS Analysis of seized samples paper impregnated 
samples in prison 
Norman et al. 
(2020a) 
LC-MS Analysis of post-mortem blood samples Rice et al. (2020) 
NMR Analysis of ‘unknown’ substance Tomažič (2020) 
LC-MS In vitro metabolism study and analysis of a case 
sample 
Yeter et al. (2020) 
LC-MS; LC-UV; IR; 
NMR 
Analysis of synthesised material Stove and 
Banister, personal 
communication 
(11) 
a GC: gas chromatography; MS: mass spectrometry; LC: liquid chromatography; IR: infrared 
spectroscopy; NMR: nuclear magnetic resonance spectroscopy; EI: electron ionisation; HR: 
high resolution; IMS: ion mobility spectrometry; UV: ultraviolet spectroscopy; LC-MS and ESI-
MS: might involve single, tandem, low, or high resolution methods of analysis. 
 
2.6 Dosage regimens  
Information on the dose and dosage regimens (14) for MDMB-4en-PINACA is limited. 
Products containing synthetic cannabinoids such as MDMB-4en-PINACA rarely state the 
correct ingredients and concentrations, as such, people who use such products will be 
unaware that they are using this substance and will be unable to obtain accurate dosage 
information.  
In addition, in respect to smoking mixtures, the process for mixing the synthetic 
cannabinoids with the plant material to make the smoking mixture can lead to dangerous 
amounts of the substances in the products. This is because producers have to guess the 
amount of substances to be added, while the mixing process makes it difficult to dilute them 
sufficiently and distribute them consistently throughout the plant material. This can result 
both in products that contain toxic amounts of the substances in general (Ernst et al. 2017; 
 
(14) Dosage regimen: is information on the formulation (dosage form), route of exposure, as well as the schedule of doses of a 
new psychoactive substance, including the amount taken each time, time between doses, and the duration of use. 
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Frinculescu et al. 2017; Langer et al. 2014: Langer et al. 2016), as well as in products where 
the solid particles of synthetic cannabinoids are clumped together, forming highly 
concentrated pockets within the plant material (Frinculescu et al. 2016; Moosmann et al. 
2015; Schäper et al. 2016). In fact, in the latter case, simply tapping a packet containing a 
smoking mixture can dislodge the substances from the plant material. In addition, paper 
(such as blotters and cards) impregnated with synthetic cannabinoids can pose a similar 
high risk of poisoning because the amount of synthetic cannabinoid can be unevenly 
distributed in different parts of the paper, sometimes forming highly concentrated sections on 
the paper (Norman, et al., 2020). These issues are made worse because the products are 
smoked or vaped, allowing the substances to be rapidly absorbed into the bloodstream and 
to reach the central nervous system and other parts of the body to cause their effects. 
Accounts from patients and people who witness poisonings suggest that in some cases a 
small number of puffs from a cigarette (‘joint‘) have been sufficient to cause severe and fatal 
poisoning. 
Together, these factors, coupled to the typically high potency of synthetic cannabinoids, 
makes it difficult for users to control the dose that they are exposed to. This can lead them to 
unintentionally administer a toxic dose. 
Reports posted on Internet forums that involve information of dosage regimens of MDMB-
4en-PINACA are limited. MDMB-4en-PINACA can be inhaled by smoking and it is expected 
that similar to related synthetic cannabinoids, that MDMB-4en-PINACA might also be 
inhaled by vaporising e-liquid solutions (‘vaping’), for example by using electronic cigarettes, 
and administered orally or sublingually (Reddit, 2020). 
The concentration of MDMB-4en-PINACA in products seized by law enforcement or from 
collected samples in Europe is currently limited (see below). The composition of products is 
likely to vary over time and place, as well as based on the specific location in the drug 
supply chain in which the sample is obtained from (for example, from the manufacturer, 
wholesaler, retailer, or at street-level markets).  
In reports to the EMCDDA, MDMB-4en-PINACA has been predominantly encountered in the 
form of smoking mixtures. Other forms included powders, liquids (including e-liquids), 
impregnated papers and cards (including blotters). Some reports did not specify the physical 
form encountered (EMCDDA, 2020b).  
According to reports received by EMCDDA, MDMB-4en-PINACA has been detected in 
combination with other synthetic cannabinoids including: 5F-MDMB-PICA (8), 4F-MDMB-
BICA (5), 4F-MDMB-BINACA (7), 5Cl-AB-PINACA (9), 5F-EMB-PICA (15), AMB-FUBINACA 
(16), AB-FUBINACA (17), Cumyl-PeGaClone (18), CUMYL-4CN-BINACA (19), Cumyl-5F-
 
(15) 5F-EMB-PICA IUPAC name: ethyl 2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3-methylbutanoate  
(16) AMB-FUBINACA IUPAC name: methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate  
(17) AB-FUBINACA IUPAC name: N-[1-amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
(18) Cumyl-PeGaClone IUPAC name: 5-pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one 
(19) CUMYL-4CN-BINACA IUPAC name: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide 
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PINACA (20) and JWH-210 (21). 
In a seizure of three ‘Spice ’samples reported by the United Kingdom and that were made in 
July 2020 in Manchester, MDMB-4en-PINACA was identified in a ratio ‘per plant material of 
1.56% to 2.09% w/w ’. The report noted that this was 1.5 to 2 times the ratio of MDMB-4en-
PINACA found in seized samples tested in June 2020. For comparison, herbal cannabis 
samples typically contain roughly 8–12% THC w/w (Freeman et al., 2020). 
During the analysis of 360 individual seized paper samples (168 seizures) from 3 Scottish 
prisons between 1 June 2018 and 27 September 2019, 146 samples (41%) were found to 
contain at least one synthetic cannabinoid receptor agonist. For MDMB-4en-PINACA, the 
reported concentration range in 22 samples was <0.07–0.58 mg/cm2 (Norman, 2020b). As of 
18 September 2020, MDMB-4en-PINACA has been detected in 97 separate seizures of 
synthetic cannabinoid impregnated papers submitted for analysis (McKenzie, 2020). MDMB-
4en-PINACA has been detected in papers in isolation but is also commonly detected with 
4F-MDMB-BINACA (7) as well as 5F-MDMB-PICA (8), both 4F-MDMB-BINACA and 5F-
MDMB-PICA, and more recently with 5F-EMB-PICA (15) (McKenzie, 2020).  
Analysis of drug samples submitted to the Welsh Emerging Drugs & Identification of Novel 
Substances Project (WEDINOS) found that MDMB-4en-PINACA was identified in e-liquids 
purchased as THC (WEDINOS, 2020). WEDINOS also reported the identification of MDMB-
4en-PINACA and flubromazolam in tablets sold as alprazolam (WEDINOS, 2020). Eighty-
four samples containing MDMB-4en-PINACA were submitted to WEDINOS between August 
2019 and September 2020. Of these, 76 samples (90%) were submitted in 2020. Fifty-seven 
of the samples (68%) submitted to WEDINOS were smoking mixtures (EMCDDA, 2020b; 
WEDINOS, 2020).  
Drug-checking services operating in Switzerland reported that MDMB-4en-PINACA was 
identified with CBD in 37 samples (between May and September 2020) sold as ‘THC 
cannabis ’or ‘THC hashish’. Nineteen samples contained other synthetic cannabinoids such 
as 5F-MDMB-PICA (8), 4F-MDMB-BINACA (7), 5F-ADBICA-A, 4F-MDMB-BICA (5) and THJ-
018 (22)(EMCDDA, 2020b; Rave it Safe, 2020; Saferparty.ch, 2020). An additional 45 
samples (23) submitted as herbal cannabis or cannabis resin (‘hashish’) tested in Switzerland 
were found to contain MDMB-4en-PINACA and other synthetic cannabinoids, according to 
the website DrugsData.org, Erowid's anonymous drug analysis programme. According to the 
same source, three powdered samples submitted to drug testing (at least one of which sold 
as heroin) from the Boston area (Massachusetts, United States) identified MDMB-4en-
PINACA in combination with fentanyl, lidocaine, caffeine, and traces of 4-ANPP in two of the 
samples, and MDMB-4en-PINACA in combination with fentanyl and lidocaine in the other 
 
(20) Cumyl-5F-PINACA IUPAC name: 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide 
(21) JWH-210 IUPAC name: (4-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone  
(22) THJ-018 IUPAC name: (naphthalen-1-yl)(1-pentyl-1H-indazol-3-yl)methanone  
(23) As of 22 November 2020  
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sample(24) (DrugsData.org, 2020). 
Whilst formal epidemiological studies have not been performed, the small number of 
anecdotal self-reported experiences on user websites suggest, that, similar to other 
synthetic cannabinoids, the dosage regimens used for MDMB-4en-PINACA can differ within 
and between individuals. Reported doses included 0.02–0.1 mg (‘vaping’) and 0.1–0.6 mg 
(sublingual) (Reddit, 2020), but it is not possible to discern typical dosage regimens. These 
also depend on the tolerance of the user, the use of other drugs, and the desired effects. 
Furthermore, the purity, amount and/or composition of the substance ingested are not 
typically known by the user. In addition, the actual composition of the substance may differ 
over time and place.  
3. Legitimate use 
3.1 Summary 
Based on the available information, it appears that MDMB-4en-PINACA is not an active 
substance in a medicinal product for human use or in a veterinary medicinal product in 
Europe. 
However, although highly unlikely, the use of MDMB-4en-PINACA as an active substance in 
medicinal products prepared extemporaneously or in investigational medicinal products 
cannot be excluded in some Member States (EMCDDA, 2020b). There is currently no 
information that suggests MDMB-4en-PINACA is used for legitimate purposes other than 
research or forensic application. 
3.2 Medical use 
Based on information from the European Medicines Agency for the initial report (EMCDDA, 
2020b), it appears that MDMB-4en-PINACA is not an active substance in: 
• a medicinal product for human use or in a veterinary medicinal product that has obtained a 
marketing authorisation in accordance with Directive 2001/83/ EC of the European 
Parliament and of the Council, Directive 2001/82/EC of the European Parliament and of 
the Council or Regulation (EC) No 726/2004 of the European Parliament and of the 
Council; 
• a medicinal product for human use or in a veterinary medicinal product that is the subject 
of an application for a marketing authorisation; 
• a medicinal product for human use or in a veterinary medicinal product whose marketing 
authorisation has been suspended by the competent authority. 
 
(24) 4-ANPP: 4-anilino-N-phenethylpiperidine (IUPAC name: N-phenyl-1-(2-phenylethyl)18iperidine-4-amine); an intermediate 
used for the synthesis of fentanyl analogues.  
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In addition, it appears that MDMB-4en-PINACA is not an active substance in the following, 
although the information, especially in relation to use in extemporaneously prepared 
products, is unknown in some cases: 
• an unauthorised medicinal product for human use in accordance with Article 5 of Directive 
2001/83/ EC or in a veterinary medicinal product prepared extemporaneously by a person 
authorised to do so under national law in accordance with point (c) of Article 10(1) of 
Directive 2001/82/EC; 
• an investigational medicinal product as defined in point (d) of Article 2 of Directive 
2001/20/EC of the European Parliament and of the Council.  
3.3 Industrial, commercial, and scientific use 
MDMB-4en-PINACA is used as an analytical reference material in clinical and forensic case 
work as well as scientific research. There is currently no information that suggests MDMB-
4en-PINACA is used for other legitimate purposes. 
As part of the initial report process, the European Chemical Agency (ECHA) and European 
Food Safety Authority (EFSA) reported to the EMCDDA that MDMB-4en-PINACA did not 
retrieve any results in their information systems (EMCDDA, 2020b). 
According to the recent critical review of MDMB-4en-PINACA published by the World Health 
Organization (WHO, 2020a), China reported that the substance is ‘being used in industrial or 
other non-medical or non-scientific use’.  
4. Pharmacological and toxicological properties 
4.1 Summary  
MDMB-4en-PINACA has been shown to act as a potent, low to sub-nanomolar full agonist at 
the cannabinoid type 1 (CB1) receptor when investigated assays in vitro. When investigated 
under identical conditions, the ester hydrolysis product (an important metabolite) was found 
to show a 233-fold drop in binding affinity compared to the parent molecule. The evaluation 
of (R)-MDMB-4en-PINACA also revealed a large drop in potency when compared to (S)-
MDMB-4en-PINACA. Data on the pharmacokinetics of MDMB-4en-PINACA in humans are 
limited to the identification of metabolites and in vitro data on metabolic stability. No studies 
were identified that have investigated the pharmacodynamics of MDMB-4en-PINACA on 
pharmacological targets other than cannabinoid receptor type 1 (CB1). Initial data obtained 
from in vivo studies suggest that the effects induced MDMB-4en-PINACA appear to be 
consistent with those observed for other synthetic cannabinoids.  
Although not formally studied, the psychological and behavioural effects of MDMB-4en-
PINACA are likely to share some similarities with those commonly reported for other 
synthetic cannabinoids, including: relaxation, euphoria, lethargy, confusion, anxiety, fear, 
distorted perception of time, depersonalisation, hallucinations, paranoid inclusions, as well 
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as dry mouth, bloodshot eyes, cardiovascular effects, nausea, vomiting and impaired motor 
performance.  
Information on the toxicological properties of MDMB-4en-PINACA could not be identified. 
Compared to cannabis, severe and fatal poisoning appears to be more common with 
synthetic cannabinoids. Poisoning symptoms may include rapid loss of 
consciousness/coma, cardiovascular effects (such as hypertension, tachycardia, 
bradycardia, chest pain, myocardial infarction, and stroke), seizures and convulsions, 
vomiting (including hyperemesis), delirium, agitation, psychosis, and, aggressive and violent 
behaviour. Sudden death has also been reported. There is no known antidote to poisoning 
caused by this substance and thus the treatment of an overdose is the same as that of 
cannabis toxicity: supportive treatment and serial reassessment of the airway and 
neurological signs. Effects reported by people who used a substance believed to be MDMB-
4en-PINACA included stimulation, sensations of feeling ‘really stoned’, craving for food, 
depersonalisation, anxiety, paranoia, sedation, and dissociation. Anecdotal reports indicated 
that the threshold dose for MDMB-4en-PINACA when inhaled by ‘vaping ’might be below the 
0.1 mg level, which suggests it is similar to other highly potent synthetic cannabinoids. The 
development of rapid tolerance has been reported and duration of effects have been 
described to last between 15–45 min when inhaled by ‘vaping’, depending on the extent of 
tolerance. The assessment of such reports is problematic not least because users cannot 
confirm the actual substance or the amount used. In general, given the difficulties of 
collecting accurate self-reported data, it should be interpreted with caution. 
The abuse liability and dependence producing potential of MDMB-4en-PINACA have not 
been studied. However, it has been suggested that consumption of synthetic cannabinoids 
can produce tolerance and withdrawal-like symptoms when use is discontinued following a 
regular use. 
4.2 Pharmacodynamics 
4.2.1 In vitro data 
Though limited, current available information from in vitro studies suggests that MDMB-4en-
PINACA binds to and activates the cannabinoid type 1 (CB1) receptor (Table 2) (25). MDMB-
4en-PINACA has also been confirmed to act as a potent, full agonist in two separate assay 
systems with activity in the low to sub-nanomolar range. Another comparison with JWH-018 
(26) revealed that MDMB-4en-PINACA activated the CB1 receptor with slightly higher potency 
(~1.6-fold) (Vikingsson and Gréen, 2020) (Table 2). The closely related 5F-MDMB-PINACA 
(5F-ADB) was shown to show comparable properties (EMCDDA, 2018; WHO, 2017). For 
comparison, MDMB-PINACA, the saturated analogue of MDMB-4en-PINACA, was more 
potent than THC but less efficacious than 5F-MDMB-PINACA with respective EC50 values of 
 
(25) Ki represents the equilibrium inhibition constant for the test drug displacing the radioligand; EC50 represents the half 
maximal effective concentration for a given substance.  
(26) JWH-018 IUPAC name: (naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 
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1.4, 171 and 0.59 nM (Banister et al., 2016). 
 
Table 2. In vitro binding and activation data at the hCB1 receptor reported for enantiopure MDMB-
4en-PINACA 
Enantiomer Ki (nM) EC50 (nM) Emax (%) Reference 
 
Not described 
(presumably (S)-MDMB-4en-PINACA)) 
 
3.26 a 
 
0.33 b 
 
112.7 
Janowski, cited in 
WHO (2020a) 
(S)-MDMB-4en-PINACA –  2.47 c 239 d Krotulski et al. 
(2020a) 
(S)-MDMB-4en-PINACA – 1.11 c 229 d Antonides et al. 
(2020) 
(S)-MDMB-4en-PINACA – 2.33 c 299 e Stove and Banister, 
personal 
communication (10) 
(R)-MDMB-4en-PINACA – 229 c 197 d Antonides et al 
(2020)  
(S)-MDMB-4en-PINACA – 16.7f 109g Vikingsson and 
Gréen (2020) 
a HEK cells 
b Forskolin-stimulated accumulation of cyclic adenosine monophosphate (cAMP) assay 
c HEK cells; β-Arrestin 2 recruitment assay 
d Relative to JWH-018 (Emax = 100%; EC50 = 14.2 nM) 
e Relative to JWH-018 (Emax = 100%; EC50 = 21.4 nM) 
f Aquerin base system; CHO cells 
g Relative to JWH-018 (Emax = 100%; EC50 = 27.2 nM) 
 
Under the same assay conditions shown in Table 2 (Antonides et al., 2020; Krotulski et al., 
2020a), (S)-5F-ADB was also shown to display high potencies in the same range: EC50 = 
1.78 nM (Emax = 331%) (Antonides et al., 2019); EC50 = 0.84 nM (Emax = 319%) (Wouters et 
al., 2019); (EC50 = 0.18 nM; Emax = 250%) (Antonides et al., 2020; Wouters et al., 2020). On 
the other hand, (R)-5F-ADB showed a ~74-fold drop in potency (EC50 = 131 nM; Emax = 
180%) compared to its (S)-counterpart (Antonides et al., 2019). The reduction in potency 
observed for (R)-MDMB-4en-PINACA (EC50 = 229 nM; Emax = 197%) was 206-fold (Table 2). 
The ester hydrolysis product of (S)-MDMB-4en-PINACA (11) was found to result in a 233-
fold drop in potency regarding receptor activation (EC50 = 576 nM; Emax = 265%, relative to 
22 
 
JWH-018) (Krotulski et al., 2020a). As shown in Section 4.5, the acidic hydrolysis product 
has also been found to be an important metabolite that might be targeted for analysis. It is 
not known whether MDMB-4en-PINACA affects other pharmacological targets, such as 
receptors, enzymes or transport processes. 
4.2.2 In vivo data 
Detailed information on the in vivo effects of MDMB-4en-PINACA could not be identified. 
Unpublished information provided to the World Health Organization for the critical review of 
MDMB-4en-PINACA (WHO, 2020a) refers to a study using 6 male ICR mice by Wiley and 
Marusich from RTI International (North Carolina, USA) and states that:  
‘In this experiment, MDMB-4en-PINACA (0.1, 1 or 10 mg/kg) was injected intraperitoneally. 
Rectal temperature was measured at 30, 45 and 60 minutes post-injection and overt 
behaviour was observed over the same period. Whereas the dose of 0.1 mg/kg did not 
reduce temperature at any time point, 1 and 10 mg/kg decreased temperature, with maximal 
decreases of −4.6  ±0.62 °C and −8.15  ±0.41 °C, respectively. In addition, some mice that 
received either 1 or 10 mg/kg were lethargic and exhibited seizures upon handling. At 1 
mg/kg, cage behaviour normalized within 2 hours; however, at 10 mg/kg, mice were still 
lethargic at 5 hours post-injection. The 10 mg/kg dose also led to gasping and aggression in 
some mice. These effects had worn off by 3 hours post-injection.’ 
These results suggest that MDMB-4en-PINACA shares similar properties to other synthetic 
cannabinoids. Cannabimimetic (i.e. Δ9-THC-like) effects commonly reported for such 
substances include hypolocomotion, antinociception, hypothermia, and catalepsy (e.g. 
Lefever et al., 2017; Wiley et al., 2017); these effects are similar to but not entirely identical 
with those observed for MDMB-4en-PINACA. 
4.3 Psychological and behavioural effects  
Information on the study of psychological and behavioural effects of MDMB-4en-PINACA in 
humans could not be identified. Based on the limited information on the pharmacological 
properties of MDMB-4en-PINACA, as well information from previous observations involving 
closely related synthetic cannabinoids such as 5F-MDMB-PINACA (4), it is likely that the 
effects of MDMB-4en-PINACA share some similarities with those commonly reported for 
cannabis but also other synthetic cannabinoids, including: relaxation, euphoria, lethargy, 
confusion, anxiety, fear, distorted perception of time, depersonalisation, hallucinations, 
paranoid delusions, as well as dry mouth, bloodshot eyes, cardiovascular effects, nausea, 
vomiting and impaired motor performance. These dose-dependent effects appear to be 
much more pronounced and severe when compared to cannabis (Ford et al., 2017; Zaurova 
et al. 2016). Specifically, psychotic episodes, confusion, paranoia, as well as aggressive and 
violent behaviour, have been reported for 5F-MDMB-PINACA (EMCDDA, 2018; WHO, 
2017).  
Effects reported by people who used a substance they believed to be MDMB-4en-PINACA 
included stimulation, sensations of feeling ‘really stoned’, craving for food, depersonalisation, 
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anxiety, paranoia, sedation, and dissociation (Reddit, 2020). The self-reported effects from 
users submitting samples containing MDMB-4en-PINACA were consistent with those 
reported for other synthetic cannabinoids, and included euphoria, relaxation, chest pains, 
irregular heartbeat, vomiting, confusion, agitation, auditory and visual hallucinations, and 
paranoia (WEDINOS, 2020).  
4.4 Safety pharmacology  
Detailed information on the safety pharmacology (ICH, 2000) of MDMB-4en-PINACA could 
not be identified. However, the available data described in this section suggest that this 
substance is a potent, full CB1 receptor agonist and that it shows mechanistic similarities 
with THC and other synthetic cannabinoids receptor agonists in vivo.  
Based on the currently information on the pharmacological properties of MDMB-4en-
PINACA and other closely related synthetic cannabinoids such as 5F-MDMB-PINACA, 
adverse effects from overdosing MDMB-4en-PINACA might include gastrointestinal (e.g. 
nausea, and vomiting (including hyperemesis)), neurological (e.g. hallucination, agitation, 
anxiety, paranoia, confusion, delusions, catatonia, lethargy, psychosis especially in 
susceptible individuals) and severe central nervous system depression (such as rapid loss of 
consciousness/coma), cardiovascular (e.g. tachycardia, hypertension, acute myocardial 
infarction and sudden cardiac death) and renal (e.g. acute kidney failure) clinical features 
(Ford et al., 2017; Hermanns-Clausen et al., 2013; Ozturk et al., 2019; Pacher et al., 2018; 
Tait et al., 2016). These effects appear to be much more pronounced and severe when 
compared to cannabis (Ford et al., 2017; Zaurova et al., 2016).  
4.5 Pharmacokinetics  
The biotransformation of MDMB-4en-PINACA has recently been investigated following 
incubation with human hepatocytes and human liver microsomes (HLM). Thirty-two 
metabolites were detected, with 11 metabolites being detected in hepatocyte samples, and 
31 in HLM. The detected metabolites were suggested to involve butanoic acid formation via 
terminal oxidation of the alkenyl chain, carboxylation, dehydrogenation, dihydrodiol 
formation, ester hydrolysis, hydrogenation, hydroxylation, and glucuronidation either alone or 
in combination (Figure 3) (Watanabe et al., 2019). The three most abundant metabolites 
were M8 (ester hydrolysis and dihydrodiol), M30 (ester hydrolysis) (13), and M20 (ester 
hydrolysis and hydroxylation) for a 5 h hepatocyte incubation and M7 (ester hydrolysis, 
dihydrodiol, and dehydrogenation), M8 (ester hydrolysis and dihydrodiol), and M3 (ester 
hydrolysis, dihydrodiol, hydroxylation, and dehydrogenation) for HLM incubation (Figure 3). 
The analysis of an authentic blood and urine sample confirmed the detection of the parent 
MDMB-4en-PINACA. Two metabolites were detected in hydrolysed urine (M8, ester 
hydrolysis and dihydrodiol; M30, ester hydrolysis), whereas one metabolite was detected in 
blood and non-hydrolysed urine (M30 and M8). The ester hydrolysis metabolite M8 was 
considered more abundant in hydrolysed urine (Watanabe et al., 2019).  
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Figure 3. Proposed metabolic pathways of MDMB-4en-PINACA (Watanabe et al., 2019). 
A separate study involving the incubation of MDMB-4en-PINACA with pooled HLMs reported 
the detection of 14 metabolites, thought to be formed via double bond oxidation, ester 
hydrolysis, N-dealkylation, hydroxylation, dehydrogenation and further oxidation to N-
pentanoic acid or combinations thereof (Yeter and Yeter, 2020). MDMB-4en-PINACA was 
detected as the parent drug in 10 of 22 authentic urine samples chosen for investigations 
(MDMB-4en-PINACA detected in 56/2150 case samples). Three of the identified main 
metabolites (double bond oxidation in combination with ester hydrolysis and hydroxylation 
reactions) were suggested as suitable urinary markers, including the ester hydrolysis 
product (13) (Yeter and Yeter, 2020). The parent molecule and its ester hydrolysis product 
have also been used as targets during the analysis of authentic blood and urine specimen 
involving post-mortem, clinical and driving under the influence of drugs cases (Krotulski et 
al., 2020a). The detection of MDMB-4en-PINACA and metabolites (not specified) has also 
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been reported during the analysis of post-mortem sample material by Rice et al. (2020). 
The pharmacological activity, if any, of the possible metabolites of MDMB-4en-PINACA is 
not known, except for the activity at the CB1 receptor of the ester hydrolysis product. 
The lipophilic nature of synthetic cannabinoids such as (S)-MDMB-4en-PINACA is reflected 
in significant plasma protein binding (99%). The intrinsic metabolic stability of (S)-MDMB-
4en-PINACA has been determined in human liver microsomes and human hepatocytes. In 
vitro half-life, microsomal clearance (CLint micr) and intrinsic clearance (CLint) with predicted in 
vivo hepatic clearance (CLH) and hepatic extraction ratio (EH) for pooled human liver 
microsome incubations were as follows: T1/2 = 5.3 min; CLint micr = 0.261 mL min-1 mg 
microsomal protein-1; CLint = 353 mL min-1 kg-1; CLH = 3.02 mL min-1 kg-1; EH = 0.14. In vitro 
half-life and intrinsic clearance (CLint) with predicted in vivo hepatic clearance (CLH) and 
hepatic extraction ratio (EH) for pooled cryopreserved human hepatocyte incubations were 
determined as follows: T1/2 = 9.1 min; CLint = 843 mL min-1 kg-1; CLH = 6.01 mL min-1 kg-1; EH 
= 0.29 (McKenzie, 2020).  
Information about the duration of effects recorded during human studies could not be 
identified. Anecdotal reports from people who used a substance they believed to be MDMB-
4en-PINACA suggest that the psychoactive effects might range between 15–45 min when 
inhaled by ‘vaping ’depending on the administered dose and whether tolerance developed 
(Reddit, 2020). 
4.6 Toxicology 
Information on the toxicological properties (including pre-clinical safety data) of MDMB-4en-
PINACA could not be identified.  
Though relevant information is lacking, the involvement of other, non-cannabinoid 
toxicological targets or unexpected drug-drug interactions in the overall pharmaco-
toxicological effects of MDMB-4en-PINACA cannot be excluded. 
There is no known antidote to poisoning caused by synthetic cannabinoids. Treatment in 
poisoning cases should be symptomatic. 
4.7 Abuse liability and dependence producing potential  
Unpublished work involving drug discrimination studies (Wiley and Marusich; RTI 
International (North Carolina, USA)) presented in the Critical Review report on MDMB-4en-
PINACA published by WHO described ‘that intraperitoneal MDMB-4en-PINACA substituted 
for Δ9-tetrahydrocannabinol (THC) in male (n = 8) and female (n = 2) C57/Bl6 mice trained to 
discriminate 5.6 mg/kg THC (intraperitoneal) from vehicle in a two nose-poke drug 
discrimination procedure. Substitution was dose-dependent, with maximal substitution (97% 
THC-aperture responding) occurring at 0.1 mg/kg and was not accompanied by effects on 
response rates. The ED50 for THC-like discriminative stimulus effects for MDMB-4en-
PINACA was 0.071 μmol/kg ‘(WHO, 2020a). These findings are consistent with other 
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synthetic cannabinoids that have shown THC-like discriminative stimulus effects in mice 
(Wiley et al., 2018). 
Further information on the abuse liability and dependence producing potential of MDMB-
4en-PINACA could not be identified. It has been suggested that consumption of synthetic 
cannabinoids can produce tolerance and withdrawal-like symptoms when regular use is 
discontinued. These include: anxiety, unstable mood, crying fits, feeling of inner emptiness, 
spatial disorientation, hyperacusis (increased sensitivity to ordinary environmental sounds), 
somatic pain, shortness of breath, hyperventilation, intense sweating and sensations of 
motor and inner restlessness.  
Anecdotal reports from people who used a substance they believed to be MDMB-4en-
PINACA suggest that tolerance develops quickly when vaped (Reddit, 2020). Given what is 
currently known about the pharmacology of synthetic cannabinoids in general, including the 
closely related 5F-MDMB-PINACA (4) (and some similarities to THC), it is reasonable to 
consider that the substance may have both a potential for abuse and dependence 
(EMCDDA, 2018). The THC-like discriminative stimulus effects of MDMB-4en-PINACA 
together with high potency binding to and activation of CB1 receptors (Section 4.2.1) are in 
alignment with anecdotal reports on the psychoactive effects of MDMB-4en-PINACA 
(Reddit, 2020), which supports the hypothesis that MDMB-4en-PINACA shows abuse 
liability similar to other synthetic cannabinoids under international and European control.  
5. Extent and patterns of use, availability, and potential for diffusion 
5.1 Summary 
There is limited information on the extent and patterns of use, availability, and potential for 
diffusion of MDMB-4en-PINACA in Europe. 
MDMB-4en-PINACA has been available on the drug market in Europe since at least 2017. 
As of November 2020, MDMB-4en-PINACA has been identified in twenty-one Member 
States as well as Norway and Turkey; 770 seizures have been reported, which include 
approximately 47 kg of powder and 4.7 kg of smoking mixtures. Although MDMB-4en-
PINACA was first identified on the drug market in 2017, it was only in 2019 that a large 
number of first identifications in Member States occurred. In addition, in 2020 there was a 
large increase in the quantity of MDMB-4en-PINACA seized by customs, with approximately 
99% of the total amount of powder seized by customs (44 kg) having occurred during the 
year. 
The available information suggests that MDMB-4en-PINACA is manufactured by chemical 
companies based in China. It is imported into Europe as bulk powders and then sold and 
distributed in wholesale and retail amounts within Europe either as a powder for processing 
into products or finished consumers products. There are three main types of products 
containing MDMB-4en-PINACA that are available on the drug market:  
• smoking mixtures, where MDMB-4en-PINACA is mixed with plant material or tobacco that 
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is then smoked or inhaled from a vaporiser (similar to herbal cannabis, the mixture is 
usually prepared for smoking as a hand-rolled cigarette (‘joint’));  
• e-liquids, where a solution of MDMB-4en-PINACA is prepared by mixing it with a solvent, 
which is then inhaled using an e-cigarette;  
• paper impregnated with MDMB-4en-PINACA, which can then be smoked or vaped. This is 
a commonly used approach to smuggle synthetic cannabinoids into prison in some 
countries.  
To a lesser extent, users may prepare similar formulations on their own using MDMB-4en-
PINACA purchased from a vendor or dealer. 
Although MDMB-4en-PINACA may be deliberately sought after by some users, in most 
cases, such as those that purchase it at street-level and/or in prison, they are likely to be 
unaware that they are using the substance which presents an inherent risk to the individuals. 
Detections of MDMB-4en-PINACA may be undetected, since the substance may not be 
routinely screened for in forensic and toxicology laboratories. Therefore, the presence of 
MDMB-4en-PINACA on the European drug market may be undetected in some areas, 
including in law enforcement seizures as well as in biological samples related to serious 
adverse events. It is also important to note that, because of differences in reporting practices 
across Europe, identifications of MDMB-4en-PINACA may be unreported to the Reitox 
national focal points and as a consequence to the EMCDDA. 
It is also important to note that, in some settings, the ongoing COVID-19 pandemic caused 
by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ECDC, 2020; 
EMCDDA, 2020d; WHO, 2020b) may have reduced the capacity of early warning systems, 
including forensic science and toxicology laboratories, to detect and report events involving 
MDMB-4en-PINACA. 
The effect of the ongoing COVID-19 pandemic (ECDC, 2020; EMCDDA, 2020d; WHO, 
2020b) on the manufacture, trafficking, distribution, and use of MDMB-4en-PINACA is 
currently unknown. However, seizures of bulk powders by European national customs 
agencies during the pandemic suggests that it continues to be imported into and distributed 
within Europe. It is conceivable that should there be a reduced availability of cannabis and 
other synthetic cannabinoids in Europe, criminal groups as well as people who use drugs, 
may use a range of replacement substances, including MDMB-4en-PINACA. 
5.2 Information from seizures 
In total, 770 seizures of MDMB-4en-PINACA, which include approximately 47 kg of powder 
and 4.7 kg of smoking mixtures, were reported to the EMCDDA by 21 Member States and 
Norway, as follows: the United Kingdom (380 seizures), Hungary (223), Germany (40), 
France (35), Sweden (20), Belgium (12), Poland (11), Bulgaria (10), Latvia (7), Lithuania (7), 
Slovakia (5), Slovenia (5), Spain (3), Austria (2), Cyprus (2), Romania (2), Croatia (1), 
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Greece (1), the Netherlands (1), Portugal (1), Italy (1) and Norway (1). In addition, Turkey 
reported 663 additional cases that may contain duplicates and have not been included in the 
count. 
The majority of the seizures comprise police cases (732), with 109 (15%) of the seizures 
taking place in prisons and other custodial settings. There were 38 customs cases reported. 
Seizures included smoking mixtures, powders, liquids, and papers impregnated with the 
substance (including blotters). Some reports did not specify physical forms. A summary is 
provided below. 
5.2.1 Customs seizures 
A total of 38 customs seizures of MDMB-4en-PINACA were reported by France (13), 
Belgium (12), Poland (4), Germany (3), Sweden (2), Bulgaria (1), Lithuania (1), the 
Netherlands (1), and Norway (1). When reported, the seizures occurred between May 2019 
and September 2020. In the majority of cases (36) no other substances were reported in the 
seizures. 
In customs seizures, MDMB-4en-PINACA was detected in powders, and smoking mixtures. 
A summary is provided below. 
Powders 
In total, 22 customs seizures, amounting to 44.5 kg were in powder form. Overall, most of 
powders were seized in 2020 (44.36 kg; 99.7%), while only 115 grams were seized in 2019.  
In total, Belgium reported 11 seizures of MDMB-4en-PINACA amounting to 44.3 kg of 
powder. These included two single seizures amounting to 16 kg each. All the seizures 
reported by Belgium originated in China and the destinations were reported as: Turkey (for 
each of the 16 kg seizures); the United Kingdom (for 3 seizures amounting to 7.2 kg); Israel 
(2, 2.7 kg); Reunion (France) (1, 500 grams); Netherlands (1, 1.5 kg); Belgium (1, 300 
grams); and Romania (1, 100 grams). No other substances were reported as identified in 
any of the seizures. 
Lithuania reported a shipment originating from Spain of MDMB-4en-PINACA in a package 
labelled ‘5CL’. 
Smoking mixtures 
Four seizures of smoking mixtures were reported, amounting to 287 g, In 2 of them 5F-
MDMB-PICA was also detected. 
Other 
For 12 seizures no physical form was specified and/or known. These amounted to 
approximately 2.6 kg. 
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5.2.2 Police seizures 
A total of 732 seizures made by police were reported by 19 Member States, as follows: the 
United Kingdom (380 seizures), Hungary (223), Germany (37), France (22), Sweden (18), 
Bulgaria (9), Latvia (7), Poland (7), Lithuania (6), Slovakia (5), Slovenia (5), Spain (3), 
Austria (2), Cyprus (2), Romania (2), Croatia (1), Greece (1), Portugal (1), and Italy (1). 
Seizures occurred between 2017 and September 2020. Where known, seizures occurred in 
2017 (1), 2018 (14), 2019 (325), and 2020 (390). The police seizures amounted to 
approximately 16 kg. In terms of quantity, material containing MDMB-4en-PINACA was 
seized mainly in 2020 (9.7 kg) and 2019 (6.2 kg). 
Out of the 732 police seizures, 109 seizures occurred in prisons, including correction houses 
and were reported by: the United Kingdom (98), Slovenia (5), Lithuania (3), Cyprus (1), 
France (1) and Germany (1). The seizures occurred between June 2019 and August 2020. 
In 100 cases, the seizures were in blotter form, including all cases reported by the United 
Kingdom, and amounted to 135 blotters. In 5 seizures, reported by Slovenia, MDMB-4en-
PINACA was detected in herbal material amounting to 11.51 grams. Other synthetic 
cannabinoids were detected in 11 of the seizures; these included: 5F-MDMB-PICA (9), 4F-
MDMB-BICA (4), 4F-MDMB-BINACA (3), and others. In the case reported by Cyprus, 14 
impregnated sheets of A4 sized paper which had been concealed inside a television were 
seized in a delivery of a package to a prison. 
The remaining 623 seizures reported by the police were detected in smoking mixtures, 
powders, blotters, and liquids. A summary is provided below (excluding seizures made in 
prison). 
Smoking mixtures 
A total of 301 seizures of smoking mixtures amounting to 4.5 kg were reported by: Hungary 
(194), the United Kingdom (49), Germany (32), Latvia (7), Sweden (7), Slovakia (5), Poland 
(3), Lithuania (2), Greece (1), and Croatia (1). Seizures occurred between 2017 and 
September 2020.  
In 67 cases, other synthetic cannabinoids were detected: mainly 5F-MDMB-PICA (39), 4F-
MDMB-BICA (11), and 4F-MDMB-BINACA (11). In 3 cases reported by the United Kingdom, 
cannabis and THC were detected. In 4 cases reported by the United Kingdom, nicotine was 
detected.  
Most of the seizures (260) were under 10 grams, but seizures ranged from 0.03 grams to 
842 grams. Germany reported MDMB-4en-PINACA in branded ‘legal-high ’type products: 
‘Pico Bello Extra Strong ’(seized in 2017, containing 5-ADB and 5-ADB-PINACA), ‘Pico Bello 
Made In Holland ’(3 seizures, containing also 5F-MDMB-PICA). Mixtures were also found in 
joints, in small non-branded grip-seal clear bags and inside paper wrappers. 
30 
 
Powders 
In total, 46 seizures of powder amounting to 2.6 kg were reported by: Hungary (17), Sweden 
(11), the United Kingdom (5), Germany (3), Spain (3), Poland (2), Cyprus (1), Lithuania (1), 
Portugal (1), Romania (1), and Italy (1). Most of the seizures (29) were under 10 g, but 
seizures ranged from 0.01 grams to approximately 1 kg.  
Only three seizures were reported to contain other substances: dimethyl sulfone (1) (27); 4F-
MDMB-BINACA (1), and 5F-MDMB-2201 (1). In a seizure reported by Italy, MDMB-4en-
PINACA was labelled incorrectly as 5F-MDMB-2201. 
Impregnated papers, including blotters 
A total of 42 seizures amounting to 150 blotters were reported by 3 Member States: the 
United Kingdom (30), Hungary (11), and Germany (1). In 11 cases, other synthetic 
cannabinoids were also detected, 5F-MDMB-PICA (9 cases), 4F-MDMB-BINACA (2) and 
AMB-FUBINACA (1). 
Liquids 
In total, 15 seizures of liquid amounting to 39 ml were reported by 3 Member States: France 
(11), the United Kingdom (3) and Hungary (1). Of these, in 11 seizures other psychoactive 
substances were detected including mainly synthetic cannabinoids. The liquids were found 
in most cases in vials, as e-liquids for vaping (10 cases), and in one case in an e-cigarette 
with a half empty cartridge. 
Other 
For 219 seizures amounting to close to 8.8 kg the physical form was not specified, reported 
as ‘other ’or unknown. These included 5 single seizures amounting to close to 1 kg each, 
reported by the United Kingdom, which occurred in February 2020. 
5.3 Information from collected samples 
A total of 15 collected samples were reported by 6 Member States: France (5 samples), 
Poland (3), Germany (2), the Netherlands (2), Slovenia (2), and Belgium (1). Of these, 7 
samples were in powder form, 4 samples were in liquid form, 1 sample was a smoking 
mixture, 1 sample was reported as ‘resin’, and for the remaining 2 samples the form was 
reported as ‘other’. 
Powders were collected as beige or yellow solids. In one case reported by Slovenia MDMB-
4en-PINACA was purchased from an internet website as ‘5-CL-ADB-A ’for the price of 21 
dollars per gram. 
 
(27) Dimethyl sulfone or methylsulfonylmethane (MSM) is a crystalline solid occasionally used in dietary supplements or as a 
cutting agent in illicit psychostimulants. It also occurs in nature. 
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All the cases where MDMB-4en-PINACA was detected in liquid form were recovered from 
poisoning cases. They were reported by France (3) and Belgium (1),.  
The 3 liquid samples reported by France were collected between September 2019 and 
January 2020 and were collected from young patients which were taken ill with acute non-
fatal poisonings.  
• In one case, the sample was sold under the street name ‘PTC ’(from the French, ‘pète ton 
crâne’) and was associated to the poisonings with probable exposure to MDMB-4en-
PINACA of two males, aged 16.  
• In another case, a commercially available bottle of a common (legal) e-liquid (‘Born to 
DYI’) was re-filled with a liquid containing MDMB-4en-PINACA and 4F-MDMB-BINACA. 
The substance was distributed among a network of 6th form students. 
• In the remaining case, a liquid containing MDMB-4en-PINACA and 4F-MDMB-BINACA 
was collected from a 17-year-old patient who had taken it with a younger friend.  
The sample reported by Belgium was in an e-liquid for vaping found on a poisoned patient. 
Along with MDMB-4en-PINACA, the sample contained five other cannabinoids and 
benzylone (28). The case occurred in July 2020. 
The Netherlands reported one herbal cannabis and one cannabis resin sample that were 
submitted for analysis at one of the drug checking services after users experienced strong 
negative side effects. Samples were purchased from street dealers in October 2020. Both 
samples contained MDMB-4en-PINACA together with THC. 
Two additional samples reported by France, which also contained 5F-MDMB-PICA, were 
collected in the overseas department and region of Mayotte and sold as ‘Chimique’. 
5.4 Information from biological samples 
Serious adverse events with confirmed exposure to MDMB-4en-PINACA from biological 
samples are discussed in sections 6.2.1. and 6.2.2. 
Sixty-four detections of MDMB-4en-PINACA in biological samples were reported by Turkey 
(36) and Hungary (28) (29). Detections included (EMCDDA 2020b):  
• 3 samples associated with non-fatal intoxications, reported by Hungary;  
• 4 cases of persons suspected of driving under the influence of drugs (including two traffic 
 
(28) Benzylone, or BMDP, is a cathinone derivative. IUPAC name: 1-(2H-1,3-benzodioxol-5-yl)-2-(benzylamino)propan-1-one. 
(29) In addition, Turkey reported 101 samples associated with non-fatal intoxications which may contain duplicates and 
therefore have not been included in the total count. 
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accidents), reported by Hungary; 
• 11 cases of drug consumption, reported by Hungary; 
• 10 cases of drug dependence, reported by Hungary (in all of the cases other substances 
were detected);  
• 36 samples taken by the law enforcement agencies, reported by Turkey. 
In addition to information from biological samples reported by the Member States, the 
following information was identified from Germany, Turkey, and the United States. 
Germany 
As shown in Table 3, the number of identifications of MDMB-4en-PINACA in authentic urine 
samples at the Institute of Forensic Medicine, Medical Centre, University of Freiburg, 
Germany, increased in the period between the third quarter of 2019 and third quarter of 
2020. These detections predominantly reflected results from routine screenings involving 
abstinence control cases within correctional and psychiatric facilities but not poisonings.  
Table 3. Detections of MDMB-4en-PINACA in authentic urine samples at the Institute of 
Forensic Medicine, Medical Centre, University of Freiburg, Germany a  
 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 
Number of samples 1720 1027 1062 873 1123 
Number of samples positive 
for synthetic cannabinoids  
227 
(13%) 
239 
(23%) 
235 
(22%) 
198 
(23%) 
268 
(24%) 
Number of samples positive 
for MDMB-4en-PINACA 
8  (3.5%)  26 (11%) 20 (9%) 76 (38%) 179 
(67%) 
a Courtesy of Prof. Volker Auwärter 
 
Turkey 
Between April and August 2019, researchers in Turkey confirmed the detection of 56 
MDMB-4en-PINACA-positive out of 2150 urine samples although case details were not 
included. The authors stated that ‘the number of MDMB-4en-PINACA-positive cases 
increased significantly compared to other months ‘(Yeter and Yeter, 2020). 
United States 
In the United States of America, MDMB-4en-PINACA was stated to have been identified in 
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at least 51 toxicology specimens (30) associated with post-mortem death investigations (34), 
driving under the influence of drugs investigations, and clinical investigations. Details about 
the cases and the proportion of positive findings out of the total number of drug tests were 
not reported (Krotulski et al. 2020b). Whether these cases included the detections reported 
in Section 6 (Krotulski et al. 2020a) was not stated. 
6. Health risks 
6.1 Summary  
Data from studies in animals or humans featuring the acute and chronic health effects of 
MDMB-4en-PINACA use could not be identified. However, it appears likely that the clinical 
features of poisonings caused by MDMB-4en-PINACA will be similar to those reported from 
other synthetic cannabinoid receptor agonist NPS resulting in gastrointestinal, neurological, 
cardiovascular, renal clinical features. These effects appear to be much more pronounced 
and severe when compared to cannabis. Similar to other synthetic cannabinoids, the use of 
MDMB-4en-PINACA with other drugs, especially central nervous system depressants (such 
as alcohol, opioids, and sedative/hypnotics) is likely to increase the risk of life-threatening 
poisoning.  
A total of eleven acute non-fatal poisonings with confirmed exposure to MDMB-4en-PINACA 
have been reported to the EMCDDA by one Member State, the United Kingdom. Exposure 
to other substances was reported in most cases, including other synthetic cannabinoids. At 
least some of the clinical features of the poisonings were consistent with exposure to 
synthetic cannabinoids. In ten of the cases, the poisoning was reported to be life-threatening 
and required hospitalisation of the patient.  
A total of twelve deaths with confirmed exposure to MDMB-4en-PINACA have been reported 
to the EMCDDA by three Member States, Hungary (8 cases), the United Kingdom (3 cases), 
and Sweden (1 case). In some of the cases, MDMB-4en-PINACA was reported to be the 
cause of death or to have contributed to the death.  
In the United States of America, analyses of 16 post-mortem blood samples identified 
MDMB-4en-PINACA (and/or its ester hydrolysis metabolite (13)) as the only synthetic 
cannabinoid in five cases with ethanol being also detected in two cases. The authors stated 
that the results from toxicology testing paired with case history showed the potential for 
MDMB-4en-PINACA to cause or contribute to impairment or death.  
There is no information on the chronic health effects of MDMB-4en-PINACA, including 
abuse liability and dependence production potential. The chronic health risks might share 
some similarities to those seen with other synthetic cannabinoids. This may include 
dependence.  
 
(30) As of October 2020.  
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6.2 Acute health effects 
Specific information about MDMB-4en-PINACA could not be identified. Based on the 
available information on the pharmacological properties of MDMB-4en-PINACA and other 
closely related synthetic cannabinoids such as 5F-MDMB-PINACA, adverse effects from 
overdosing MDMB-4en-PINACA might include gastrointestinal (e.g. nausea and vomiting 
(including hyperemesis)), neurological (e.g. hallucination, agitation, anxiety, paranoia, 
confusion, delusions, catatonia, lethargy, psychosis (including in susceptible individuals) and 
severe central nervous system depression (such as rapid loss of consciousness/coma)), 
cardiovascular (e.g. tachycardia, hypertension, acute myocardial infarction and sudden 
cardiac death) and renal (e.g. acute kidney failure) clinical features (Ford et al., 2017; 
Hermanns-Clausen et al., 2013; Ozturk et al., 2019; Pacher et al., 2018; Skryabin and 
Vinnikova, 2018; Tait et al., 2016). These effects appear to be much more pronounced and 
severe when compared to cannabis (Ford et al., 2017; Zaurova et al., 2016).  
As discussed in section 2.6, due to the typically high potency of synthetic cannabinoids and 
inadvertent high dose users may be exposed to from products, it is difficult for users to 
control the dose that they are exposed to. This can lead them to unintentionally administer a 
toxic dose. 
Some individuals may use MDMB-4en-PINACA in combination with other drugs (either 
intentionally or unintentionally) and are unlikely to be aware of the substance(s) being 
ingested and doses used (by whatever route). Similar to other synthetic cannabinoids, the 
use of MDMB-4en-PINACA with other drugs, especially central nervous system depressants 
(such as alcohol, opioids, and sedative/hypnotics) is likely to increase the risk of life-
threatening poisoning. 
Some of the features of poisoning — particularly loss of consciousness, respiratory 
depression, and behavioural effects — may place users at additional risks, such as choking 
on/aspirating vomit, drowning, falling, hypothermia as a result of falling unconscious outside 
in cold weather, and self-inflicted violence/injury (e.g. EMCDDA; 2017; Tait et al., 2016; 
Yeter, 2017). 
6.2.1 Acute poisonings 
Acute poisoning reported by the Member States  
A total of 11 acute non-fatal poisonings with confirmed exposure to MDMB-4en-PINACA 
were reported by one Member State, the United Kingdom (31)(32). The cases occurred 
between January and August 2020. Of the cases, nine were male and two were female. The 
males were aged between 19 and 60 (mean 36; median 32.5). The females were aged 31 
and 35.  
 
(31) In addition, France reported two acute intoxications with probable exposure to MDMB-4en-PINACA. These cases are not 
discussed further in this report. 
(32) In addition, Germany reported one intoxication involving MDMB-4en-PINACA. This case is not discussed further in this 
report. 
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All cases included clinical features of poisoning similar to those reported for other synthetic 
cannabinoids, such as confusion, tachycardia, respiratory insufficiency, reduced conscious 
level, seizures, abnormal sweating, agitation, aggression. However, in all cases other 
substances were also identified in the biological samples taken from the patients, including 
one or more other synthetic cannabinoids, which may account, at least in part, for the 
observed effects. Other substances identified in the patients, include: 
• other synthetic cannabinoids: 4F-MDMB-BICA (5 cases), 5F-EMB-PICA (3 cases), 4F-
MDMB-BINACA (3 cases), 5F-MDMB-PICA (2 cases), AB-FUBINACA (1 case);  
• benzodiazepines: diazepam (8 cases), temazepam (5 cases), oxazepam (4 cases, 
flubromazolam (3 cases), etizolam (2 cases), flualprazolam (1 case), clonazolam (1 case), 
chlordiazepoxide (1 case); 
• opioids: methadone (6 cases), morphine (4 cases), codeine (3 cases), alfentanyl (1 case); 
• other drugs: pregabalin (6 cases), THC (6 cases), cocaine/ benzoylecgonine (4 cases), 
ketamine (2 cases), methamphetamine (1 case). 
In ten of the cases, the poisoning was considered life threatening and required 
hospitalisation of the patients. 
Acute poisonings identified from other sources 
In the United States of America, a summary involving the qualitative detection of MDMB-
4en-PINACA and/or its ester hydrolysis metabolite (13) was published with details 
summarised in Table 4 (Krotulski et al., 2020a). Eight cases from suspected clinical 
toxicology investigations revealed the detection of the MDMB-4en-PINACA ester hydrolysis 
metabolite in urine samples. No further information about the cases was reported and in 
seven of these cases other synthetic cannabinoid receptor agonist metabolites could be 
detected although it was unclear whether the suggested parent molecules could have also 
arisen from substances other than methyl esters (Table 4).  
6.2.2 Deaths 
Deaths reported by the Member States 
A total of 12 deaths with confirmed exposure to MDMB-4en-PINACA were reported by three 
Member States: Hungary (8), the United Kingdom (3), and Sweden (1)(33). The cases 
occurred between January 2019 and August 2020. Of the deaths, ten were male and two 
were female. The males were aged between 20 and 41 (mean 28; median 27.5); the 
females were aged 31.  
 
(33) In addition, Germany reported four deaths involving MDMB-4en-PINACA. These cases are not discussed further in this 
report. 
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In all cases other substances were identified, including: 
• other synthetic cannabinoids: 4F-MDMB-BICA (8 cases); 5F-MDMB-PICA (4 cases); 
‘fluoro‘-MDMB-PICA (1 case) 
• benzodiazepines: clonazepam metabolite (1 case), midazolam metabolite(1 case), 
flualprazolam (1 case); diazepam (1 case); oxazepam (1 case); temazepam (1 case); 
• opioids: morphine (1 case); codeine (1 case);  
• other drugs and alcohol: THC (2 cases); alcohol (2 cases); ethylhexedrone (1 case); 
methylphenidate (1 case); ritalinic acid (1 case); alpha-PiHP (1 case); bupropion (1 case); 
cocaine (1 case); pregabalin (1 case). 
Four of the cases were found dead, in one case the individual fell from a balcony. In some of 
the cases it was reported that the individuals collapsed and/or had seizure before the death. 
A cause of death was reported in all cases: 
• in the cases reported by Hungary, the reported causes of death were: cardiac arrest due to 
substance overdose (4 cases), acute heart failure (3 cases), and asphyxiation following 
aspirating vomit (1 case); 
• in the cases reported by the United Kingdom, the reported causes of death were: synthetic 
cannabinoid (MDMB-4en-PINACA) and alcohol toxicity (1 case), synthetic cannabinoid use 
(1 case) and mixed drug toxicity (1 case); 
• in the case reported by Sweden, the cause of death was trauma from a fall where the 
contribution from drugs present could not be determined. 
Deaths identified from other sources  
United Kingdom 
A case report published in the medical literature from the United Kingdom involved the death 
of a 40-year old female known to use drugs, including synthetic cannabinoid products 
(‘Mamba’) who was found dead. Analysis of biological samples from the decedent identified 
(unpreserved blood) of methadone (711 ng/mL), methadone metabolite (EDDP, (67 ng/mL), 
pregabalin (7.9 mg/L), mirtazapine (3229 ng/mL), 4F-MDMB-BINACA (7) metabolites, along 
with MDMB-4en-PINACA and metabolites. The cause of death was ruled mixed drug toxicity 
(Rice et al., 2020).  
United States of America 
The detection of MDMB-4en-PINACA in two blood samples obtained from post-mortem 
cases (no details available) has been reported (Krotulski et al., 2019). A follow-up summary 
involving the detection of MDMB-4en-PINACA and/or its ester hydrolysis metabolite (13) has 
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been published (Krotulski et al., 2020a). The results from the analysis of 25 biofluid samples 
(16 x post-mortem, 8 x clinical, 1 x DUID (34)) are summarised in Table 4 which shows that 
16 out of 25 forensic were post-mortem investigations (Table 4). The average age was 36 
years (SD 11 years; range 21–57 years). Twelve individuals were female, seven were male, 
and the gender was not reported in six cases.  
In four post-mortem samples, MDMB-4en-PINACA (or its ester hydrolysis metabolite (13)) 
was the only synthetic cannabinoid receptor agonist/metabolite detected. One case involved 
a death in custody where the manner of death was ruled accidental (no details reported); the 
only additional finding was caffeine. One case states a history of lupus with a history of 
heavy ethanol and ‘Kush ‘use; the individual was found unresponsive after drinking ethanol 
(ethanol concentration not reported). In the third case, no other information was reported.  
In two additional cases, ethanol was also detected in femoral blood samples together with 
the MDMB-4en-PINACA ester hydrolysis metabolite. In one case, the person was found in a 
jail cell with a bottle of green liquid (caffeine and phenytoin also detected) whereas the other 
involved the use of a suspected synthetic cannabinoid receptor agonist-containing product, 
as well as ‘an illicit substance ‘prior to death; ethanol was stated as the only toxicological 
finding. In the remaining 11 post-mortem samples, either MDMB-4en-PINACA (and/or its 
ester hydrolysis metabolite) was detected with other controlled substances (e.g. 
amphetamine, methamphetamine, and fentanyl) or it was detected in conjunction with other 
synthetic cannabinoids and/or metabolites and controlled substances (Table 4). The authors 
stated that the results from toxicology testing paired with case history showed the potential 
for MDMB-4en-PINACA to cause or contribute to impairment or death (Krotulski et al., 
2020a).  
Table 4. Cases involving detections of MDMB-4en-PINACA and other substances 
(modified from Krotulski et al. (2020a)) 
Date 
Received 
Case 
Type 
Ag
e 
Se
x 
US 
Stat
e 
Matrix Toxicology Results Case History 
21 May 
2019 
Clinic
al 50 F UT Urine 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
4F-MDMB-BINACA 3,3-
dimethylbutanoic acid, 
MMB-FUBINACA 3-
methylbutanoic acid, 5F-
MDMB-PINACA 3,3-
dimethylbutanoic acid 
N/A 
24 May Clinic 50 F UT Urine MDMB-4en-PINACA 3,3- N/A 
 
(34) DUID: driving under the influence of drugs  
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2019 al dimethylbutanoic acid 
23 July 
2019 PM 45 M IN 
Peripher
al Blood 
MDMB-4en-PINACA, 
caffeine 
Death in 
custody; 
manner of 
death: 
accidental 
07 Aug 
2019 PM 31 F IN Blood 
MDMB-4en-PINACA, 5F-
MDMB-PICA, BZE (<100 
ng/mL), caffeine, cotinine 
Pedestrian in 
motor vehicle 
accident 
27 Aug 
2019 PM 46 F TX 
Heart 
Blood MDMB-4en-PINACA 
History of 
lupus; history of 
heavy ethanol 
and ‘Kush‘ use; 
found 
unresponsive 
after drinking 
ethanol 
17 Sep 
2019 PM 42 F OH Blood 
MDMB-4en-PINACA, 5F-
MDMB-PICA 
Undetermined 
death 
28 Sep 
2019 
Clinic
al 23 F UT Urine 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
5F-MDMB-PICA 3,3-
dimethylbutanoic acid 
N/A 
04 Oct 
2019 
Clinic
al 36 F UT Urine 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
4F-MDMB-BINACA 3,3-
dimethylbutanoic acid, 
5F-MDMB-PICA 3,3-
dimethylbutanoic acid 
N/A 
05 Oct 
2019 
Clinic
al 30 F UT Urine 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
4F-MDMB-BINACA 3,3-
dimethylbutanoic acid, 
5F-MDMB-PICA 3,3-
dimethylbutanoic acid 
N/A 
12 Oct 
2019 
Clinic
al 21 F MI Urine 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
5F-MDMB-PICA 3,3-
dimethylbutanoic acid 
N/A 
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12 Oct 
2019 
Clinic
al 21 M MI Urine 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid N/A 
17 Oct 
2019 
Clinic
al 24 M UT Urine 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
4F-MDMB-BINACA 3,3-
dimethylbutanoic acid, 
5F-MDMB-PICA 3,3-
dimethylbutanoic acid 
N/A 
17 Oct 
2019 PM 44 M TX 
Femoral 
Blood 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
ethanol (50 mg/dL), 
caffeine, phenytoin 
Found in jail 
cell with a 
bottle of green 
liquid 
08 Nov 
2019 PM 31 M AR 
Cardiac 
Blood 
MDMB-4en-PINACA, 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
ethanol (48 mg/dL), 
methamphetamine (630 
ng/mL), amphetamine (83 
ng/mL), nicotine 
Suspected drug 
overdose; 
history of 
synthetic drug 
use 
13 Nov 
2019 PM 43 M WI 
Iliac 
Blood 
MDMB-4en-PINACA, 
MDMB-4en-PINACA  
3,3-dimethylbutanoic 
acid, THC (2.3 ng/mL), 
fentanyl (48 ng/mL), 
nicotine 
Found 
unresponsive 
at residence; 
undetermined 
death 
03 Dec 
2019 PM 
N/
A 
N/
A FL 
Heart 
Blood 
MDMB-4en-PINACA, 
MDMB-4en-PINACA  
3,3-dimethylbutanoic 
acid, 4F-MDMB-BINACA, 
5F-MDMB-PICA 
N/A 
10 Dec 
2019 PM 32 F TX 
Heart 
Blood 
MDMB-4en-PINACA, 4F-
MDMB-BINACA,  
5F-MDMB-PICA 
Homeless 
individual; 
history of 
‘Kush‘ use 
08 Jan 
2020 PM 57 M CO 
Femoral 
Blood 
MDMB-4en-PINACA 3,3-
dimethylbutanoic acid, 
ethanol (84 mg/dL) 
Possible illicit 
drug abuse; 
possible ‘Black 
Mamba‘ use 
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08 Jan 
2020 DUID 
N/
A 
N/
A TX Blood 
MDMB-4en-PINACA, 
MDMB-4en-PINACA  
3,3-dimethylbutanoic 
acid, 4F-MDMB-BINACA, 
5F-MDMB-PICA, 5-OH-
MDMB-PICA, 5F-MDMB-
PICA 3,3-
dimethylbutanoic acid 
Driving while 
intoxicated; 
suspected 
synthetic 
cannabinoid 
use 
08 Jan 
2020 PM 
N/
A 
N/
A PA 
Femoral 
Blood 
MDMB-4en-PINACA, 4F-
MDMB-BINACA N/A 
10 Jan 
2020 PM 27 M LA Blood 
MDMB-4en-PINACA, 4F-
MDMB-BINACA,  
4OH-MDMB-BINACA, 
5F-MDMB-PICA,  
5-OH-MDMB-PICA, 
cotinine 
Suspected drug 
overdose; 
possible ‘Mojo‘ 
use; history of 
diabetes 
15 Jan 
2020 PM 
N/
A 
N/
A AL 
Femoral 
Blood 
MDMB-4en-PINACA, 4F-
MDMB-BINACA,  
4-OH-MDMB-BINACA 
N/A 
15 Jan 
2020 PM 
N/
A 
N/
A AL 
Femoral 
Blood 
MDMB-4en-PINACA, 
MMB-FUBINACA  
3-methylbutanoic acid 
N/A 
17 Jan 
2020 PM 
N/
A 
N/
A DC 
Heart 
Blood MDMB-4en-PINACA N/A 
20 Jan 
2020 PM 33 F IN Blood 
MDMB-4en-PINACA, 4F-
MDMB-BINACA,  
fentanyl (11 ng/mL), 
xylazine (6.1 ng/mL), 
diazepam (29 ng/mL), 
morphine (53 ng/mL), 
naloxone, cotinine 
N/A 
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PM: post-mortem; DUID: driving under the influence of drugs; N/A: not available; F: female; M: 
male: BZE: benzoylecgonine: THC: Δ9-THC; (–)-trans-Δ⁹-tetrahydrocannabinol; 4F-MDMB-BINACA: 
methyl (2-{[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate; MMB-
FUBINACA (AMB-FUBINACA, FUB-AMB): methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-
carbonyl}amino)-3-methylbutanoate; 5F-MDMB-PINACA (5F-ADB): methyl 2-{[1-(5-fluoropentyl)-1H-
indazole-3-carbonyl]amino}-3,3-dimethylbutanoate; 5F-MDMB-PICA (5F-MDMB-2201): methyl 2-{[1-
(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate  
 
6.2.3 Driving and operating machinery under influence 
Hungary reported 4 identifications of MDMB-4en-PINACA in biological samples reported as 
suspected driving under the influence of drugs (including two traffic accidents). 
The results from the analysis of one blood sample taken from a person suspected to be 
driving while intoxicated in the United States of America identified MDMB-4en-PINACA and 
its ester hydrolysis metabolite but also other synthetic cannabinoids and metabolites (Table 
4) (Krotulski et al., 2020a). Further details were not available. 
Driving while under the influence of synthetic cannabinoids places people who use these 
substances and others at risk of injury (Capron, 2016; Kaneko, 2017; Karinen et al., 2015; 
Musshoff et al., 2014). The extent of impairment in cases involving motor vehicle accidents 
was considered severe for a range of different synthetic cannabinoids: examples from 
reports included: loss of consciousness, lane travel, causing collisions, erratic driving, 
speeding, poor coordination and focus, confusion, aggressiveness, slow response to 
questioning, incoherent speech, excited states such as agitation, shouting, and stereotyped 
behaviours (Capron, 2016; Kaneko, 2017). Similarly, the operation of machinery while under 
the influence of synthetic cannabinoids may place the people who use these substances and 
others at risk of injury. 
6.3 Chronic health effects  
Specific information about MDMB-4en-PINACA could not be identified. Similar to other 
synthetic cannabinoids, chronic use has been associated with greater risks for developing 
mental health disorder than cannabis (Cohen and Weinstein, 2018; Skryabin and Vinnikova, 
2018), which may include dependence. Acute and chronic use of synthetic cannabinoids has 
also been associated with cases displaying detrimental cardiovascular health (Ozturk et al., 
2019; Pacher et al., 2018).  
7. Social risks 
Whilst there is limited information for MDMB-4en-PINACA, the social risks might share some 
similarities with cannabis and other synthetic cannabinoids. Of particular note is that 
synthetic cannabinoids are increasingly used by vulnerable groups, such as prisoners and 
people experiencing homelessness. Reports suggest that this has caused new health and 
social problems as well as exacerbated existing ones for these groups. For example, in 
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prisons, alongside the adverse health effects, such as acute poisonings, the market in 
synthetic cannabinoids has been linked to an increase in bullying and debt, as well as 
aggression and violence. In some cases this has caused a serious threat to the overall 
safety and security of the prison environment (Blackman and Bradley, 2017; HMIP, 2015; 
Ralphs et al., 2017; User Voice, 2016). As such, it is a concern that MDMB-4en-PINACA has 
been seized in prisons and other custodial settings in at least 6 Member States and, that 
overall, approximately 15 % of all the seizures of MDMB-4en-PINACA made by police 
occurred in these settings.  
7.1 Individual social risks  
While there is no specific information on whether the use of MDMB-4en-PINACA causes 
individual social risks, any such risks may have some similarities with those associated with 
cannabis and other synthetic cannabinoids. These may impact on education or career, 
family or other personal and social relationships and may result in marginalisation. 
7.2 Possible effects on direct social environment 
While there is no specific information on the possible effects of MDMB-4en-PINACA on the 
direct social environment, the behavioural effects of synthetic cannabinoids include reports 
of aggressive and violent behaviour. This may place users and others at risk of injury. 
7.3 Possible effects on society as a whole 
While there is no specific information on the possible effects of MDMB-4en-PINACA on 
society as a whole, as noted, the behavioural effects of synthetic cannabinoids include 
reports of aggressive and violent behaviour. In particular, concern was expressed in this 
regard to use in certain environments such as prisons and psychiatric institutions.  
In prisons, alongside the adverse health effects, the market in synthetic cannabinoids has 
been linked to an increase in aggression, violence, bullying, and debt. In some cases this 
has caused a serious threat to the overall safety and security of the prison environment.  
Due to the lack of data, it is not possible at this time to estimate the social risk associated 
with the trafficking and distribution of MDMB-4en-PINACA. 
7.4 Economic costs 
There is no information on the health and social costs related to MDMB-4en-PINACA. As 
MDMB-4en-PINACA is a synthetic cannabinoid, any such costs may have some similarities 
with those associated with the use of cannabis and other synthetic cannabinoids. 
7.5 Possible effects related to the cultural context, for example marginalisation 
There is no information on the possible effects of MDMB-4en-PINACA related to the cultural 
context. As MDMB-4en-PINACA is a synthetic cannabinoid, any such effects may have 
some similarities with those associated with the use of cannabis and other synthetic 
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cannabinoids. 
7.6 Possible appeal to specific population groups within the general population 
There is limited information on the possible appeal to specific population groups. As MDMB-
4en-PINACA is a synthetic cannabinoid, it could be expected that suppliers as well as users 
who are looking for ‘legal ’substitutes for cannabis and replacements for controlled synthetic 
cannabinoids, may be interested in MDMB-4en-PINACA. This may include individuals 
subject to drug testing (such as drivers, prisoners, those in drug treatment, and those 
subject to workplace drug testing), as commonly used drug tests may be unable to detect 
the compounds. 
In addition, reports suggest that in some areas, high risk drug users and other vulnerable 
groups, such as prisoners and people experiencing homelessness, may specifically seek out 
synthetic cannabinoids as they are readily available and have gained a reputation for 
causing profound intoxication while being comparatively cheaper to other drugs. In addition, 
synthetic cannabinoids, particularly when impregnated on to paper, can be easy to smuggle 
into prison and other custodial settings. Investigations involving the analysis of impregnated 
papers and cards seized in three Scottish prisons suggested that MDMB-4en-PINACA (first 
identification in June 2019) is currently the most prevalent synthetic cannabinoid receptor 
agonist MDMB-4en-PINACA (McKenzie, 2020). 
Although limited, there is some information to suggest a recent increase in vaping of 
synthetic cannabinoids using electronic cigarettes by young people, including teenagers, in 
some Member States; in some cases, the users beIieve that they were using cannabidiol 
(CBD) or THC. 
Similar to other new psychoactive substances, it also appears that there is interest in 
MDMB-4en-PINACA by people who experiment with a range of substances (so-called 
psychonauts). 
7.7 Involvement of criminal groups in the manufacture, distribution and distribution 
methods, and trafficking 
There is no information whether or not criminal groups are involved in the manufacture, 
trafficking, and distribution of MDMB-4en-PINACA within Europe (EMCDDA, 2020b). The 
effect of the ongoing COVID-19 pandemic (ECDC, 2020; EMCDDA, 2020d; WHO, 2020b) 
on the manufacture, trafficking, distribution, and use of MDMB-4en-PINACA is currently 
unknown. However, seizures of bulk powders by European national customs agencies 
during the pandemic suggests that it continues to be imported into and distributed within 
Europe. It is possible, that in case of a reduced availability of cannabis and other synthetic 
cannabinoids in Europe, criminal groups, as well as drug users, may use a range of 
replacement substances, including MDMB-4en-PINACA. 
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8. Other relevant information 
8.1 Information on restrictive measures 
8.1.1 International restrictive measures 
At international level, MDMB-4en-PINACA is not controlled under the United Nations Single 
Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol, or the Convention 
on Psychotropic Substances of 1971 (‘United Nations system’) (UNODC, 2020a; 
UNODC,2020b). MDMB-4en-PINACA was assessed at the 43rd meeting of the WHO Expert 
Committee on Drug Dependence (ECDD) that was held on 12–16 October 2020 (WHO, 
2020a).  
8.1.2 National restrictive measures 
Thirteen Member States (Bulgaria, Czechia, Denmark, Estonia, Greece, Ireland, Malta, the 
Netherlands, Portugal, Romania, Slovakia, Slovenia, and Spain) reported that MDMB-4en-
PINACA is not subject to restrictive measures at national level (EMCDDA, 2020b). 
MDMB-4en-PINACA is subject to restrictive measures in fifteen Member States:  
• in Croatia, Cyprus, Finland, France, Italy, Latvia, Luxembourg, Poland, Sweden, and the 
United Kingdom the substance is controlled under drug control legislation;  
• in Lithuania it is controlled under medicines legislation;  
• in Austria, Belgium, Germany, and Hungary it is controlled by new psychoactive substance 
legislation.  
In addition, MDMB-4en-PINACA is controlled under medicines legislation in Norway and 
under drug control legislation in Turkey (EMCDDA, 2020b). 
It is unknown if MDMB-4en-PINACA is controlled in China, where at least some of the 
substance on the European market has been sourced from. 
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